Gilead finally prices its Covid-19 drug
By pricing remdesivir at $2,340 for a five-day course Gilead has kept investors on side, but others will be disappointed.
Rare diseases dominate catalysts for the smallest companies
Our final look at third-quarter events focuses this time on the smallest players, with data from Amryt, Ovid, Bellus and more.
Diabetes prevention signal emerges for Farxiga
SGLT2 inhibitors primarily treat diabetes, with benefits also seen in heart and kidney diseases. Might they also help prevent diabetes in the first place?
Important catalysts approach for smaller biotechs
Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.
Merck and Pfizer square up for pneumococcal vaccine fight
The rivals have taken different strategies with next-gen pneumococcal vaccines, which will be fighting for a blockbuster market that is Pfizer’s to lose.
US FDA approval tracker: several early decisions in May
Last month the FDA greenlit four oncology approvals early and the first GnRH antagonist in uterine fibroids.
Asco 2020 – Enhertu impresses, but can it live up to high hopes?
As three Asco presentations confirm the Her2-targeting agent's potency, Daiichi Sankyo and Astrazeneca lay out an ambitious development programme.
Added firepower could signal a spending spree for Sanofi
Speculation that Sanofi is gearing up for acquisitions could grow after it banks billions from its Regeneron stake sale.
Medtech venture backers play it safe
Liquid biopsy developer Grail exemplifies 2020’s trend of sizeable mid-stage financings.
